clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-18-22clinvest-519Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWВозможность применения прямых пероральных антикоагулянтов для профилактики тромбоэмболических событий у пациентов с COVID-19Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19https://orcid.org/0000-0003-0623-7263ОтделеновВ. А.OtdelenovV. A.

Отделенов Виталий Александрович – доцент кафедры клинической фармакологии и терапии. SPIN-код: 8357-5770

Москва

Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770

Moscow

https://orcid.org/0000-0002-9307-4994МирзаевК. Б.MirzaevK. B.

Мирзаев Карин Бадавиевич  – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8308-7599

Москва

Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599

Moscow

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian Federation20202710202004SФармаCOVID1822Copyright © Отделенов В.А., Мирзаев К.Б., Сычёв Д.А., 20202020Отделенов В.А., Мирзаев К.Б., Сычёв Д.А.Otdelenov V.A., Mirzaev K.B., Sychev D.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/519

Госпитализированным пациентам с COVID-19, ранее не принимавшим прямые пероральные антикоагулянты (ПОАК) по показаниям, зарегистрированным в инструкции по медицинскому применению нецелесообразно назначать ПОАК для профилактики тромбозов у пациентов с COVID-19 в связи с отсутствием результатов клинических исследований, значимыми потенциальными взаимодействиями.

Hospitalized patients with COVID-19 who have not previously received DOAK by it is not advisable to prescribe POAC for the prevention of thrombosis in patients with COVID-19 due to the lack of clinical trial results, significant potential interactions.

коронавируспрямые пероральные антикоагулянтыCOVID-19coronavirusdirect oral anticoagulantsCOVID-19ReferencesDeng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020 Mar 20. DOI: 10.1097/CM9.0000000000000824Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020 Mar 20. DOI: 10.1097/CM9.0000000000000824Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020 Dec;9(1):687-690. DOI: 10.1080/22221751.2020.1741327Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020 Dec;9(1):687-690. DOI: 10.1080/22221751.2020.1741327Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. DOI:10.1001/jamainternmed.2020.0994Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. DOI:10.1001/jamainternmed.2020.0994American Society of Hematology. COVID-19 and coagulopathy: frequently asked questions. From the ASH website. (Version 2.0; last updated April 14, 2020) URL: https://www.hematology.org/covid-19/covid-19-andcoagulopathy (дата обращения: 04.05.2020)American Society of Hematology. COVID-19 and coagulopathy: frequently asked questions. From the ASH website. (Version 2.0; last updated April 14, 2020) URL: https://www.hematology.org/covid-19/covid-19-andcoagulopathy (дата обращения: 04.05.2020)Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-1026. DOI: 10.1111/jth.14810Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-1026. DOI: 10.1111/jth.14810Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. DOI: 10.1111/jth.14768Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. DOI: 10.1111/jth.14768Временные методические рекомендации Министерства здравоохранения РФ по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020). URL: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf (дата обращения: 04.05.2020)Временные методические рекомендации Министерства здравоохранения РФ по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020). URL: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf (дата обращения: 04.05.2020)Yale School Of Medicine. COVID-19 Treatment Algorithm. URL: https://files-profile.medicine.yale.edu/documents/e91b4e5c-ae56-4bf1-8d5fe674b6450847 (дата обращения: 04.05.2020)Yale School Of Medicine. COVID-19 Treatment Algorithm. URL: https://files-profile.medicine.yale.edu/documents/e91b4e5c-ae56-4bf1-8d5fe674b6450847 (дата обращения: 04.05.2020)UW Medicine COVID-19 ICU Care Guidelines 4_15_2020 URL: https://covid-19.uwmedicine.org/Screening%20and%20Testing%20Algorithms/09c%20-%20COVID-19%20ICU%20Care%20Guidelines%204_15_2020.pdf (дата обращения: 04.05.2020)UW Medicine COVID-19 ICU Care Guidelines 4_15_2020 URL: https://covid-19.uwmedicine.org/Screening%20and%20Testing%20Algorithms/09c%20-%20COVID-19%20ICU%20Care%20Guidelines%204_15_2020.pdf (дата обращения: 04.05.2020)Yale School Of Medicine. COVID-19 Treatment Algorithm. URL: https://files-profile.medicine.yale.edu/documents/e91b4e5c-ae56-4bf1-8d5fe674b6450847 (дата обращения: 04.05.2020)Yale School Of Medicine. COVID-19 Treatment Algorithm. URL: https://files-profile.medicine.yale.edu/documents/e91b4e5c-ae56-4bf1-8d5fe674b6450847 (дата обращения: 04.05.2020)Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of the American College of Cardiology. 2020;75(23):2950-2973, DOI: 10.1016/j.jacc.2020.04.031Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of the American College of Cardiology. 2020;75(23):2950-2973, DOI: 10.1016/j.jacc.2020.04.031Mount Sinai COVID-19 Anticoagulation Algorithm. Version 1.1 (April 9, 2020). URL: https://emergencymedicinecases.com/wp-content/uploads/2020/04/COVID-19-Anticoagulation-Algorithm-version_final_1.1.pdf (дата обращения 06.05.2020)Mount Sinai COVID-19 Anticoagulation Algorithm. Version 1.1 (April 9, 2020). URL: https://emergencymedicinecases.com/wp-content/uploads/2020/04/COVID-19-Anticoagulation-Algorithm-version_final_1.1.pdf (дата обращения 06.05.2020)Clinicaltrials.gov Search Results URL: https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=DOAC+OR+rivaroxaban+OR+apixaban+OR+dabigatran&cntry=&state=&city=&dist= (дата обращения 04.05.2020)Clinicaltrials.gov Search Results URL: https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=DOAC+OR+rivaroxaban+OR+apixaban+OR+dabigatran&cntry=&state=&city=&dist= (дата обращения 04.05.2020)Clinicaltrials.gov NCT04351724: Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT) URL: https://clinicaltrials.gov/ct2/show/NCT04351724 (дата обращения 04.05.2020)Clinicaltrials.gov NCT04351724: Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT) URL: https://clinicaltrials.gov/ct2/show/NCT04351724 (дата обращения 04.05.2020)Clinicaltrials.gov NCT04333407: Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS) URL: https://clinicaltrials.gov/ct2/show/NCT04333407 (дата обращения 04.05.2020)Clinicaltrials.gov NCT04333407: Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS) URL: https://clinicaltrials.gov/ct2/show/NCT04333407 (дата обращения 04.05.2020)Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost. 2020 Jun;18(6):1320-1323. DOI: 10.1111/jth.14871Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost. 2020 Jun;18(6):1320-1323. DOI: 10.1111/jth.14871

The authors declare that there are no conflicts of interest present.